Nucleus Capital

General Partners Dr. Isabella Fandrych and Maximilian Schwarz run the firm. Fandrych focuses on Neo Industrials and corporate relationships; Schwarz leads Food Tech and Programmable Biology. Principal Dr. Carolina Villa handles technical due diligence for biology deals, with particular expertise in bioprocess scale-up and techno-economic analysis. The firm's website states founders work only with decision-makers — implying the GP group makes all investment calls directly.

Nucleus positions itself as a first-check investor that engages before a company's direction is encoded, which means much of its pipeline likely originates from academic and technical founder networks rather than later-stage syndication. The community of industry leaders listed on its site — including operators such as Raffael Wohlgensinger (Formo) and Dr. Patricia Bubner (Orbillion Bio) — serves as an explicit sourcing and validation layer for deep-tech deals. Its dual-region Europe–US focus suggests a blend of university spinout, research-institute, and frontier-cluster origination.

Nucleus Capital is structured as an asset manager, not a family office. It raises external capital from limited partners and invites additional LPs to join its community. The firm's own materials distinguish it as a venture firm purpose-built for deep-tech — rejecting the generalist SaaS playbook — rather than a vehicle for a single family's wealth.

The firm writes first checks, explicitly leading or co-leading pre-seed and seed rounds with commitments of up to €1M. It describes itself as engaging when direction is still being encoded — which in practice means pre-product, pre-revenue, and often pre-institutional syndicate formation. The concentrated portfolio and thesis-driven posture discourage later-stage follow-on deployment as a primary strategy.

Nucleus's stated sector focus — Programmable Biology, Food Technology, and Neo Industrials — excludes enterprise SaaS, consumer internet, fintech, and generalist software. The firm is explicit that its support model is built for scientific ventures, and it actively rejects the SaaS playbook for deep-tech. That has the effect of avoiding any sector where capital efficiency alone, rather than technical risk and industrial scaling, is the dominant underwriting criterion.

Nucleus states it leads or co-leads rounds, which implies active syndication with other venture firms rather than operating as a solo first-check writer. Its naming of four portfolio companies — Formo, Planet A Foods, Cambrium, and Cradle — suggests it participates in rounds with other institutional investors, though the firm does not disclose co-investors publicly. The ‘first believers’ framing indicates a preference for setting round terms alongside founders rather than following a lead.

No philanthropic foundation, real-asset arm, or parallel vehicle is disclosed. The firm invites limited partners to join its community and offers portfolio-company job listings, but there is no public evidence of a separate impact fund, donor-advised structure, or adjacent operating business.